How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies. They are unique and require specific expertise.” FIH studies involve a lot of risk.
110 
Let's personalize your content